{"transactions":[{"id":691206,"issuer":{"id":4564,"kind":"organization","name":"Braveheart Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-08-11T21:27:59.000Z","date":"2026-08-07","kind":"exercise","planned":false,"acquired":false,"shares":40000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-4.38 basis upon the closing of the Issuer's initial public offering on August 7, 2026 without payment of consideration. The Series A Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-4.38 basis upon the closing of the Issuer's initial public offering on August 7, 2026 without payment of consideration. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-4.38 basis upon the closing of the Issuer's initial public offering on August 7, 2026 without payment of consideration. The Series A Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\"). OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9132420},"source":{"system":"sec-edgar","filing":"0000947871-26-000782","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000782/ownership.xml","form_type":"4"}},{"id":691205,"issuer":{"id":4564,"kind":"organization","name":"Braveheart Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:27:59.000Z","date":"2026-08-07","kind":"purchase","planned":false,"acquired":true,"shares":273333,"price":18,"value":4919994.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":273333,"source":{"system":"sec-edgar","filing":"0000947871-26-000782","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000782/ownership.xml","form_type":"4"}},{"id":691204,"issuer":{"id":4564,"kind":"organization","name":"Braveheart Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:27:59.000Z","date":"2026-08-07","kind":"purchase","planned":false,"acquired":true,"shares":1666667,"price":18,"value":30000006.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\"). OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":11901826,"source":{"system":"sec-edgar","filing":"0000947871-26-000782","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000782/ownership.xml","form_type":"4"}},{"id":691203,"issuer":{"id":4564,"kind":"organization","name":"Braveheart Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:27:59.000Z","date":"2026-08-07","kind":"exercise","planned":false,"acquired":true,"shares":9132420,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-4.38 basis upon the closing of the Issuer's initial public offering on August 7, 2026 without payment of consideration. The Series A Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\"). OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":10235159,"source":{"system":"sec-edgar","filing":"0000947871-26-000782","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000782/ownership.xml","form_type":"4"}},{"id":738328,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2026-06-15T22:12:04.000Z","date":"2026-06-11","kind":"purchase","planned":false,"acquired":true,"shares":208333,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 9, 2026, the Issuer announced a public offering of an aggregate of 10,879,376 shares of common stock (\"Shares\") at a price of $4.00 per Share and, in lieu of Shares to certain investors, pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 7,870,624 Shares at a price of $3.9999 per Pre-Funded Warrant. The Pre-Funded Warrant have an exercise price of $0.0001 per share and are exercisable at any time after the date of issuance. The public offering closed on June 11, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5303908,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":208333},"source":{"system":"sec-edgar","filing":"0000947871-26-000625","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000625/ownership.xml","form_type":"4"}},{"id":738327,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2026-06-15T22:12:04.000Z","date":"2026-06-11","kind":"purchase","planned":false,"acquired":true,"shares":1041667,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 9, 2026, the Issuer announced a public offering of an aggregate of 10,879,376 shares of common stock (\"Shares\") at a price of $4.00 per Share and, in lieu of Shares to certain investors, pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 7,870,624 Shares at a price of $3.9999 per Pre-Funded Warrant. The Pre-Funded Warrant have an exercise price of $0.0001 per share and are exercisable at any time after the date of issuance. The public offering closed on June 11, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\"). OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":26519541,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":1041667},"source":{"system":"sec-edgar","filing":"0000947871-26-000625","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000625/ownership.xml","form_type":"4"}},{"id":745170,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2026-06-10T00:58:33.000Z","date":"2026-06-08","kind":"exercise","planned":false,"acquired":false,"shares":3073298,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. The Reporting Persons also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares or, if so elected by Reporting Persons, Pre-Funded Warrants. The price per Share and accompanying Common Warrant was $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant was $0.8676. On June 8, 2026, the Reporting Persons exercised their Common Warrants in exchange for an equal amount of Pre-Funded Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":3073298},"source":{"system":"sec-edgar","filing":"0000947871-26-000615","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000615/ownership.xml","form_type":"4"}},{"id":745169,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2026-06-10T00:58:33.000Z","date":"2026-06-08","kind":"exercise","planned":false,"acquired":false,"shares":15366490,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. The Reporting Persons also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares or, if so elected by Reporting Persons, Pre-Funded Warrants. The price per Share and accompanying Common Warrant was $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant was $0.8676. On June 8, 2026, the Reporting Persons exercised their Common Warrants in exchange for an equal amount of Pre-Funded Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\"). OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":15366490},"source":{"system":"sec-edgar","filing":"0000947871-26-000615","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000615/ownership.xml","form_type":"4"}},{"id":745168,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2026-06-10T00:58:33.000Z","date":"2026-06-08","kind":"exercise","planned":false,"acquired":true,"shares":3073298,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. The Reporting Persons also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares or, if so elected by Reporting Persons, Pre-Funded Warrants. The price per Share and accompanying Common Warrant was $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant was $0.8676. On June 8, 2026, the Reporting Persons exercised their Common Warrants in exchange for an equal amount of Pre-Funded Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5095575,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":3073298},"source":{"system":"sec-edgar","filing":"0000947871-26-000615","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000615/ownership.xml","form_type":"4"}},{"id":745167,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2026-06-10T00:58:33.000Z","date":"2026-06-08","kind":"exercise","planned":false,"acquired":true,"shares":15366490,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. The Reporting Persons also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares or, if so elected by Reporting Persons, Pre-Funded Warrants. The price per Share and accompanying Common Warrant was $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant was $0.8676. On June 8, 2026, the Reporting Persons exercised their Common Warrants in exchange for an equal amount of Pre-Funded Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\"). OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":25477874,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":15366490},"source":{"system":"sec-edgar","filing":"0000947871-26-000615","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000615/ownership.xml","form_type":"4"}},{"id":1051847,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2025-09-03T01:52:10.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":3073298,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. The Reporting Persons also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares. The price per Share and accompanying Common Warrant is $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant is $0.8676."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3073298,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":3073298},"source":{"system":"sec-edgar","filing":"0000947871-25-000840","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000840/ownership.xml","form_type":"4"}},{"id":1051846,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2025-09-03T01:52:10.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":15366490,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. The Reporting Persons also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares. The price per Share and accompanying Common Warrant is $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant is $0.8676."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\"). OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":15366490,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":15366490},"source":{"system":"sec-edgar","filing":"0000947871-25-000840","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000840/ownership.xml","form_type":"4"}},{"id":1051845,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2025-09-03T01:52:10.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":2022277,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. The Reporting Persons also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares. The price per Share and accompanying Common Warrant is $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant is $0.8676."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2022277,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":2022277},"source":{"system":"sec-edgar","filing":"0000947871-25-000840","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000840/ownership.xml","form_type":"4"}},{"id":1051844,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2025-09-03T01:52:10.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":10111384,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. The Reporting Persons also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares. The price per Share and accompanying Common Warrant is $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant is $0.8676."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\"). OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":10111384,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":10111384},"source":{"system":"sec-edgar","filing":"0000947871-25-000840","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000840/ownership.xml","form_type":"4"}},{"id":1051843,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-03T01:52:10.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":1051021,"price":0.8677,"value":911970.9217,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1051021,"source":{"system":"sec-edgar","filing":"0000947871-25-000840","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000840/ownership.xml","form_type":"4"}},{"id":1051842,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-03T01:52:10.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":5255106,"price":0.8677,"value":4559855.4762,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\"). OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5255106,"source":{"system":"sec-edgar","filing":"0000947871-25-000840","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000840/ownership.xml","form_type":"4"}},{"id":1375916,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Simple Agreement for Future Equity","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":false,"shares":74613,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"These shares are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\") issued upon the conversion of an outstanding SAFE in the amount of $268,606.84, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors is the managing member of GP IX. By virtue of such relationships, OrbiMed Advisors and GP IX may be deemed to have voting and investment power over the securities held by OPI IX and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F6","text":"These shares are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\") issued upon the conversion of an outstanding SAFE in the amount of $268,606.84, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors is the managing member of GP IX. By virtue of such relationships, OrbiMed Advisors and GP IX may be deemed to have voting and investment power over the securities held by OPI IX and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These shares are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\") issued upon the conversion of an outstanding SAFE in the amount of $268,606.84, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors is the managing member of GP IX. By virtue of such relationships, OrbiMed Advisors and GP IX may be deemed to have voting and investment power over the securities held by OPI IX and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"These shares are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\") issued upon the conversion of an outstanding SAFE in the amount of $268,606.84, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors is the managing member of GP IX. By virtue of such relationships, OrbiMed Advisors and GP IX may be deemed to have voting and investment power over the securities held by OPI IX and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These shares are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\") issued upon the conversion of an outstanding SAFE in the amount of $268,606.84, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors is the managing member of GP IX. By virtue of such relationships, OrbiMed Advisors and GP IX may be deemed to have voting and investment power over the securities held by OPI IX and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":74613},"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375915,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Simple Agreement for Future Equity","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":false,"shares":230753,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"These shares are held of record by OPI VIII issued upon the conversion of an outstanding SAFE in the amount of $830,712.12, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F5","text":"These shares are held of record by OPI VIII issued upon the conversion of an outstanding SAFE in the amount of $830,712.12, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These shares are held of record by OPI VIII issued upon the conversion of an outstanding SAFE in the amount of $830,712.12, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"These shares are held of record by OPI VIII issued upon the conversion of an outstanding SAFE in the amount of $830,712.12, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held of record by OPI VIII issued upon the conversion of an outstanding SAFE in the amount of $830,712.12, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":230753},"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375914,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Simple Agreement for Future Equity","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":false,"shares":389078,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"These shares are held of record by OPI VII issued upon the conversion of an outstanding SAFE in the amount $1,400,681.04, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F4","text":"These shares are held of record by OPI VII issued upon the conversion of an outstanding SAFE in the amount $1,400,681.04, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These shares are held of record by OPI VII issued upon the conversion of an outstanding SAFE in the amount $1,400,681.04, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"These shares are held of record by OPI VII issued upon the conversion of an outstanding SAFE in the amount $1,400,681.04, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held of record by OPI VII issued upon the conversion of an outstanding SAFE in the amount $1,400,681.04, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":389078},"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375913,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Simple Agreement for Future Equity","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":false,"shares":215146,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"These shares are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\") issued upon the conversion of a SAFE in the amount of $688,465.75, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"These shares are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\") issued upon the conversion of a SAFE in the amount of $688,465.75, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These shares are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\") issued upon the conversion of a SAFE in the amount of $688,465.75, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These shares are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\") issued upon the conversion of a SAFE in the amount of $688,465.75, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\") issued upon the conversion of a SAFE in the amount of $688,465.75, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":215146},"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375912,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Simple Agreement for Future Equity","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":false,"shares":323916,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"These shares are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\") issued upon the conversion of an outstanding simple agreement for future equity (\"SAFE\") in the amount of $1,036,534.25, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\") issued upon the conversion of an outstanding simple agreement for future equity (\"SAFE\") in the amount of $1,036,534.25, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These shares are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\") issued upon the conversion of an outstanding simple agreement for future equity (\"SAFE\") in the amount of $1,036,534.25, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These shares are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\") issued upon the conversion of an outstanding simple agreement for future equity (\"SAFE\") in the amount of $1,036,534.25, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\") issued upon the conversion of an outstanding simple agreement for future equity (\"SAFE\") in the amount of $1,036,534.25, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":323916},"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375911,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"grant","planned":false,"acquired":true,"shares":155120,"price":4,"value":620480.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F9","text":"These shares are held of record by OPI IX issued upon the closing of the Offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These shares are held of record by OPI IX issued upon the closing of the Offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2677256,"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375910,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"grant","planned":false,"acquired":true,"shares":479736,"price":4,"value":1918944.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F8","text":"These shares are held of record by OPI VIII issued upon the closing of the Offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These shares are held of record by OPI VIII issued upon the closing of the Offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2522136,"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375909,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"grant","planned":false,"acquired":true,"shares":808894,"price":4,"value":3235576.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F7","text":"These shares are held of record by OPI VII issued upon the closing of the Offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These shares are held of record by OPI VII issued upon the closing of the Offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2042400,"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375908,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":true,"shares":74613,"price":3.6,"value":268606.8,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F6","text":"These shares are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\") issued upon the conversion of an outstanding SAFE in the amount of $268,606.84, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors is the managing member of GP IX. By virtue of such relationships, OrbiMed Advisors and GP IX may be deemed to have voting and investment power over the securities held by OPI IX and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These shares are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\") issued upon the conversion of an outstanding SAFE in the amount of $268,606.84, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors is the managing member of GP IX. By virtue of such relationships, OrbiMed Advisors and GP IX may be deemed to have voting and investment power over the securities held by OPI IX and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1233506,"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375907,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":true,"shares":230753,"price":3.6,"value":830710.8,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F5","text":"These shares are held of record by OPI VIII issued upon the conversion of an outstanding SAFE in the amount of $830,712.12, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held of record by OPI VIII issued upon the conversion of an outstanding SAFE in the amount of $830,712.12, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1158893,"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375906,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":true,"shares":389078,"price":3.6,"value":1400680.8,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F4","text":"These shares are held of record by OPI VII issued upon the conversion of an outstanding SAFE in the amount $1,400,681.04, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held of record by OPI VII issued upon the conversion of an outstanding SAFE in the amount $1,400,681.04, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":928140,"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375905,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":true,"shares":215146,"price":3.2,"value":688467.2,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"These shares are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\") issued upon the conversion of a SAFE in the amount of $688,465.75, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\") issued upon the conversion of a SAFE in the amount of $688,465.75, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":539062,"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375904,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":true,"shares":323916,"price":3.2,"value":1036531.2,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\") issued upon the conversion of an outstanding simple agreement for future equity (\"SAFE\") in the amount of $1,036,534.25, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\") issued upon the conversion of an outstanding simple agreement for future equity (\"SAFE\") in the amount of $1,036,534.25, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":323916,"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}}]}